

PLEASE JOIN US

Different by Design: The Pharmacology Story of INGREZZA® (valbenazine) capsules in the Treatment of Tardive Dyskinesia

PROGRAM INFORMATION

Saturday, May 21, 2022

7:30 pm–9:00 pm CT

Churchill Room

Second Floor

Hilton New Orleans Riverside Hotel

New Orleans, LA

Dinner will be provided by Neurocrine Biosciences, Inc.

Please visit us at Booth 2049

THERAPEUTIC UPDATE

This is an informational event provided by Neurocrine Biosciences, Inc. Participants cannot claim CME credit for attending this informational event and participation may be subject to reporting under the Sunshine Act. The Industry Sponsored Therapeutic Update's content and the views expressed therein are those of Neurocrine Biosciences, Inc. and not of APA.

As required by the U.S. Sunshine Act, Neurocrine will track and report to government agencies the cost of meals provided to individual healthcare professionals in connection with attendance at this promotional educational activity. This information will be made publicly available. If you do not want the meal, please opt out when registering.

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

PRESENTED BY



Stephen M. Stahl, MD, PhD, DSc (Hon)

Clinical Professor of Psychiatry and Neuroscience
University of California, Riverside, School of Medicine
Riverside, CA

Adjunct Professor of Psychiatry
University of California, San Diego
La Jolla, CA

Director of Psychopharmacology
Statewide Clinical Operations
California Department of State Hospitals System
Sacramento, CA

Chairman, Neuroscience Education Institute
Chairman, The Arbor Scientia Group
Carlsbad, CA



Stuart Isaacson, MD

Clinical Associate Professor of Neurology
Herbert Wertheim College of Medicine
Florida International University
Miami, FL

Director
Parkinson's Disease and Movement Disorders Center of
Boca Raton
Boca Raton, FL

PROGRAM OBJECTIVES

- > Attend a master class in the mechanism of disease of tardive dyskinesia (TD) explained by a psychiatrist and neurologist
- > Understand the proposed mechanism of action of INGREZZA® (valbenazine) capsules, including a putative interaction with the neurobiology of TD
- > Take an expert-led tour of the pharmacology of INGREZZA, highlighting its binding profile and pharmacokinetic characteristics

WARNINGS & PRECAUTIONS (continued)

Parkinsonism

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction ($\geq 5\%$ and twice the rate of placebo) is somnolence. Other adverse reactions ($\geq 2\%$ and $>$ Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying INGREZZA full Prescribing Information or visit <https://www.neurocrine.com/ingrezzapi>.